The mystery surrounding the intentions of the chief executive of AstraZeneca PLC, one of the world’s largest pharmaceutical firms, remains…a mystery.
Two days after an Israeli news report said Chief Executive Pascal Soriot had agreed to take the top job at a rival drug giant, Israel-based Teva Pharmaceutical Industries Ltd., AstraZeneca continues to say it won’t comment, labeling that report — and more recent reports that he is staying on — as market rumors and speculation.
A spokesman late Friday said Dr. Soriot would host the presentation of the company’s midyear financial results, expected later this month. But the spokesman declined to say whether that indicated Dr. Soriot was sticking around for the longer term.
A spokesman for Teva said it also wouldn’t comment on market rumors.
Shares of AstraZeneca fell sharply Thursday, after an Israeli news site, Calcalist, reported the day before that Dr. Soriot had agreed to take the top job at Teva. They ended London trading down more than 3%. Despite the steep stock market drop, AstraZeneca has repeatedly stopped short of denying the report.
On Friday, shares finished lower for the second day running, falling another 0.29%, amid the uncertainty.
By Chip Cummins
Source: Market Watch
CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.
FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.
Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.
